Drug Availability Update
Further to DrugAlert Volume 448, HPS Pharmacies wish to give notice that all suppliers are continuing to experience a supply interruption for bleomycin 15,000 IU vials as follows:
|Product||ARTG||Expected Return Date|
|Cipla Bleomycin 15k||220440||End June 2020|
|DBLTM; Bleomycin 15000IU||42569||Mid-late April 2020|
An internationally registered brand of bleomycin vials has been approved for supply under Section 19A of the Therapeutic Goods Act 1989. There are some important differences in the labelling and administration of this product. The internationally registered product is only to be used via the intramuscular, intravenous, and subcutaneous routes. While the strength of Australian products is expressed in international units (IU), the strength of the internationally registered brand is expressed in United States Pharmacopoeia units (USP units). The conversion factor is shown below:
Bleomycin 15 USP units = Bleomycin 15,000 IU
Please note that Section 19A alternatives are subject to a longer lead-time and different pricing as they must be sourced internationally.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies.